Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Optical Measurement of Changes in Intracellular Calcium.

Brown JE, De Weer P, Salzberg BM.

Biophys J. 2019 Jul 5. pii: S0006-3495(19)30543-0. doi: 10.1016/j.bpj.2019.06.034. [Epub ahead of print] No abstract available.

PMID:
31353037
2.

Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.

Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD.

Am J Gastroenterol. 2018 Nov;113(11):1678-1688. doi: 10.1038/s41395-018-0202-9. Epub 2018 Jul 19.

PMID:
30022113
3.

Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW Jr, Langholff W, Sandborn WJ.

Inflamm Bowel Dis. 2018 Feb 15;24(3):490-501. doi: 10.1093/ibd/izx072.

4.

Reminiscences of time spent with Amiram Grinvald.

Salzberg BM.

Neurophotonics. 2017 Jul;4(3):031201. doi: 10.1117/1.NPh.4.3.031201. Epub 2017 Jul 28.

5.

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.

Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W.

Lancet. 2017 Jul 8;390(10090):135-144. doi: 10.1016/S0140-6736(17)30930-3. Epub 2017 May 17. Erratum in: Lancet. 2019 Dec 22;392(10165):2696.

PMID:
28527704
6.

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group.

N Engl J Med. 2016 Nov 17;375(20):1946-1960.

7.

Two-Photon Excitation of Fluorescent Voltage-Sensitive Dyes: Monitoring Membrane Potential in the Infrared.

Fisher JA, Salzberg BM.

Adv Exp Med Biol. 2015;859:427-53. doi: 10.1007/978-3-319-17641-3_17. Review.

PMID:
26238063
8.

Imaging Submillisecond Membrane Potential Changes from Individual Regions of Single Axons, Dendrites and Spines.

Popovic M, Vogt K, Holthoff K, Konnerth A, Salzberg BM, Grinvald A, Antic SD, Canepari M, Zecevic D.

Adv Exp Med Biol. 2015;859:57-101. doi: 10.1007/978-3-319-17641-3_3. Review.

9.

Pioneers in Neurophotonics: Special Section Honoring Professor Lawrence B. Cohen.

Salzberg BM, Zecevic D.

Neurophotonics. 2015 Apr;2(2):021001. doi: 10.1117/1.NPh.2.2.021001. No abstract available.

10.

Functional ryanodine receptors in the membranes of neurohypophysial secretory granules.

McNally JM, Custer EE, Ortiz-Miranda S, Woodbury DJ, Kraner SD, Salzberg BM, Lemos JR.

J Gen Physiol. 2014 Jun;143(6):693-702. doi: 10.1085/jgp.201311110.

11.

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ.

Am J Gastroenterol. 2014 Feb;109(2):212-23. doi: 10.1038/ajg.2013.441. Epub 2014 Jan 7.

PMID:
24394749
12.

The challenge of connecting the dots in the B.R.A.I.N.

Devor A, Bandettini PA, Boas DA, Bower JM, Buxton RB, Cohen LB, Dale AM, Einevoll GT, Fox PT, Franceschini MA, Friston KJ, Fujimoto JG, Geyer MA, Greenberg JH, Halgren E, Hämäläinen MS, Helmchen F, Hyman BT, Jasanoff A, Jernigan TL, Judd LL, Kim SG, Kleinfeld D, Kopell NJ, Kutas M, Kwong KK, Larkum ME, Lo EH, Magistretti PJ, Mandeville JB, Masliah E, Mitra PP, Mobley WC, Moskowitz MA, Nimmerjahn A, Reynolds JH, Rosen BR, Salzberg BM, Schaffer CB, Silva GA, So PT, Spitzer NC, Tootell RB, Van Essen DC, Vanduffel W, Vinogradov SA, Wald LL, Wang LV, Weber B, Yodh AG.

Neuron. 2013 Oct 16;80(2):270-4. doi: 10.1016/j.neuron.2013.09.008.

13.

EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging.

Faubion WA Jr, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME.

Am J Gastroenterol. 2013 Dec;108(12):1891-900. doi: 10.1038/ajg.2013.354. Epub 2013 Oct 15. Erratum in: Am J Gastroenterol. 2014 May;109(5):780.

PMID:
24126633
14.

Carbon monoxide inhalation increases microparticles causing vascular and CNS dysfunction.

Xu J, Yang M, Kosterin P, Salzberg BM, Milovanova TN, Bhopale VM, Thom SR.

Toxicol Appl Pharmacol. 2013 Dec 1;273(2):410-7. doi: 10.1016/j.taap.2013.09.019. Epub 2013 Sep 30.

15.

Microparticles generated by decompression stress cause central nervous system injury manifested as neurohypophysial terminal action potential broadening.

Yang M, Kosterin P, Salzberg BM, Milovanova TN, Bhopale VM, Thom SR.

J Appl Physiol (1985). 2013 Nov;115(10):1481-6. doi: 10.1152/japplphysiol.00745.2013. Epub 2013 Sep 19.

16.

Measuring intrinsic optical signals from Mammalian nerve terminals.

Salzberg BM, Muschol M, Kosterin P, Obaid AL.

Cold Spring Harb Protoc. 2012 Dec 1;2012(12). pii: pdb.prot072355. doi: 10.1101/pdb.prot072355.

PMID:
23209144
17.

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ.

Am J Gastroenterol. 2012 Sep;107(9):1409-22. doi: 10.1038/ajg.2012.218. Epub 2012 Aug 14.

18.

Long-lasting intrinsic optical changes observed in the neurointermediate lobe of the mouse pituitary reflect volume changes in cells of the pars intermedia.

Kosterin P, Obaid AL, Salzberg BM.

Neuroendocrinology. 2010;92(3):158-67. doi: 10.1159/000314619. Epub 2010 Jun 16.

19.

Optical recording of electrical activity in guinea-pig enteric networks using voltage-sensitive dyes.

Obaid AL, Salzberg BM.

J Vis Exp. 2009 Dec 4;(34). pii: 1631. doi: 10.3791/1631.

20.

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.

Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ.

Inflamm Bowel Dis. 2010 Apr;16(4):620-9. doi: 10.1002/ibd.21084.

PMID:
19714757
21.

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators.

Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206. Epub 2009 Mar 31.

22.

Two-photon excitation of potentiometric probes enables optical recording of action potentials from mammalian nerve terminals in situ.

Fisher JA, Barchi JR, Welle CG, Kim GH, Kosterin P, Obaid AL, Yodh AG, Contreras D, Salzberg BM.

J Neurophysiol. 2008 Mar;99(3):1545-53. doi: 10.1152/jn.00929.2007. Epub 2008 Jan 2.

23.

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.

Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J.

Gastroenterology. 2007 Nov;133(5):1414-22. Epub 2007 Aug 21.

PMID:
17920064
24.

A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency.

Keshavarzian A, Mayer L, Salzberg B, Garone M, Finkelstein W, Cappa J, Brand M, Hain J, Zelinger D, Hegedus R, Diamond RH, Campbell U, Lane C, Stang P, Watson J, Cominelli F.

Gastroenterol Hepatol (N Y). 2007 May;3(5):381-90.

25.

A mechanical spike accompanies the action potential in Mammalian nerve terminals.

Kim GH, Kosterin P, Obaid AL, Salzberg BM.

Biophys J. 2007 May 1;92(9):3122-9. Epub 2007 Feb 16.

26.

Celecoxib for the prevention of sporadic colorectal adenomas.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators.

N Engl J Med. 2006 Aug 31;355(9):873-84.

27.

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ.

Clin Gastroenterol Hepatol. 2006 May;4(5):621-30. Erratum in: Clin Gastroenterol Hepatol. 2006 Jul;4(7):931.

PMID:
16678077
28.

Properties of new, long-wavelength, voltage-sensitive dyes in the heart.

Salama G, Choi BR, Azour G, Lavasani M, Tumbev V, Salzberg BM, Patrick MJ, Ernst LA, Waggoner AS.

J Membr Biol. 2005 Nov;208(2):125-40.

29.

Changes in FAD and NADH fluorescence in neurosecretory terminals are triggered by calcium entry and by ADP production.

Kosterin P, Kim GH, Muschol M, Obaid AL, Salzberg BM.

J Membr Biol. 2005 Nov;208(2):113-24.

PMID:
16645741
30.

Optical recording of electrical activity.

Salzberg BM.

J Membr Biol. 2005 Nov;208(2):89-90. No abstract available.

PMID:
16645738
31.

Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.

Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ.

Am J Gastroenterol. 2006 May;101(5):1030-8.

PMID:
16606351
32.

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.

Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS.

Gut. 2006 Nov;55(11):1568-74. Epub 2006 Apr 7.

33.

Near infrared two-photon excitation cross-sections of voltage-sensitive dyes.

Fisher JA, Salzberg BM, Yodh AG.

J Neurosci Methods. 2005 Oct 15;148(1):94-102. Epub 2005 Aug 29.

PMID:
16129493
34.

Optical studies of nicotinic acetylcholine receptor subtypes in the guinea-pig enteric nervous system.

Obaid AL, Nelson ME, Lindstrom J, Salzberg BM.

J Exp Biol. 2005 Aug;208(Pt 15):2981-3001. Erratum in: J Exp Biol. 2005 Aug;208(Pt 16):3219.

35.

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.

Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):373-84.

36.

A finite state model for respiratory motion analysis in image guided radiation therapy.

Wu H, Sharp GC, Salzberg B, Kaeli D, Shirato H, Jiang SB.

Phys Med Biol. 2004 Dec 7;49(23):5357-72.

PMID:
15656283
37.

An ultra-stable non-coherent light source for optical measurements in neuroscience and cell physiology.

Salzberg BM, Kosterin PV, Muschol M, Obaid AL, Rumyantsev SL, Bilenko Y, Shur MS.

J Neurosci Methods. 2005 Jan 30;141(1):165-9.

PMID:
15585300
38.

Novel naphthylstyryl-pyridium potentiometric dyes offer advantages for neural network analysis.

Obaid AL, Loew LM, Wuskell JP, Salzberg BM.

J Neurosci Methods. 2004 Apr 30;134(2):179-90.

PMID:
15003384
39.
40.

Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.

Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR.

Am J Gastroenterol. 2002 Oct;97(10):2577-84.

PMID:
12385442
41.

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.

Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR; ISIS 2302-CS9 Investigators.

Gut. 2002 Jul;51(1):30-6.

42.

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US; RHIL-11 Crohn's Study group.

Aliment Pharmacol Ther. 2002 Mar;16(3):399-406.

43.
44.

Caffeine interaction with fluorescent calcium indicator dyes.

Muschol M, Dasgupta BR, Salzberg BM.

Biophys J. 1999 Jul;77(1):577-86.

45.

Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.

Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US.

Gastroenterology. 1999 Jul;117(1):58-64.

PMID:
10381910
46.
50.

Microsecond response of a voltage-sensitive merocyanine dye: fast voltage-clamp measurements on squid giant axon.

Salzberg BM, Obaid AL, Bezanilla F.

Jpn J Physiol. 1993;43 Suppl 1:S37-41.

PMID:
8271515

Supplemental Content

Loading ...
Support Center